Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Application Number	Priority Date	Filing Date	Title
US201361825477P	2013-05-20	2013-05-20
PCT/US2014/038847WO2014189973A2 (en)	2013-05-20	2014-05-20	Anti-transferrin receptor antibodies and methods of use

Publication Number	Publication Date
SG11201509566RAtrue SG11201509566RA (en)	2015-12-30

Family

ID=50983167

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG11201509566RASG11201509566RA (en)	2013-05-20	2014-05-20	Anti-transferrin receptor antibodies and methods of use
SG10202003997UASG10202003997UA (en)	2013-05-20	2014-05-20	Anti-transferrin receptor antibodies and methods of use

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG10202003997UASG10202003997UA (en)	2013-05-20	2014-05-20	Anti-transferrin receptor antibodies and methods of use

Country Status (25)

Country	Link
US (3)	US9708406B2 (en)
EP (3)	EP3594240B1 (en)
JP (1)	JP6612214B2 (en)
KR (1)	KR102293064B1 (en)
CN (1)	CN105358578B (en)
AR (1)	AR096364A1 (en)
AU (3)	AU2014268726B2 (en)
CA (1)	CA2908743C (en)
CL (1)	CL2015003406A1 (en)
CR (1)	CR20150618A (en)
EA (1)	EA038367B1 (en)
ES (1)	ES2970063T3 (en)
HK (1)	HK1215584A1 (en)
HR (1)	HRP20240107T1 (en)
HU (1)	HUE065593T2 (en)
IL (2)	IL242088B2 (en)
MA (1)	MA38632B1 (en)
MX (1)	MX380520B (en)
PE (2)	PE20151926A1 (en)
PH (2)	PH12021550015A1 (en)
PL (1)	PL3594240T3 (en)
SG (2)	SG11201509566RA (en)
TW (1)	TWI573805B (en)
UA (1)	UA119235C2 (en)
WO (1)	WO2014189973A2 (en)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3489261B1 (en)	2012-08-24	2020-10-21	The Regents of The University of California	Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
JP6557664B2 (en)	2014-01-06	2019-08-07	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	Monovalent blood-brain barrier shuttle module
CA2967830A1 (en)	2014-11-14	2016-05-19	Ossianix, Inc.	Tfr selective binding compounds and related methods
CN107250158B (en)*	2014-11-19	2022-03-25	基因泰克公司	Anti-transferrin receptor/anti-BACE 1 multispecific antibodies and methods of use
EP3221362B1 (en)	2014-11-19	2019-07-24	F.Hoffmann-La Roche Ag	Anti-transferrin receptor antibodies and methods of use
DK3292149T3 (en)*	2015-05-04	2022-02-28	Cytomx Therapeutics Inc	ACTIVATIBLE ANTI-CD71 ANTIBODIES AND METHODS OF USING IT
TW201718647A (en)*	2015-06-16	2017-06-01	建南德克公司	Anti-CLL-1 antibodies and methods of use
BR112017027965A2 (en)	2015-06-24	2018-08-28	Japan Chem Res	receptor antibody, fusion protein, DNA fragment, expression vector, cell, receptor antibody complex, uses of a receptor antibody and fusion protein, and methods for treating a disorder and disease.
WO2016208696A1 (en)	2015-06-24	2016-12-29	Ｊｃｒファーマ株式会社	Fusion protein containing bdnf
MY199136A (en)*	2015-06-24	2023-10-17	Hoffmann La Roche	Anti-transferrin receptor antibodies with tailored affinity
AR106189A1 (en)	2015-10-02	2017-12-20	Hoffmann La Roche	BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE
PE20231655A1 (en)*	2015-10-02	2023-10-17	Hoffmann La Roche	BISPECIFIC ANTIBODIES AGAINST HUMAN CD20 AND THE HUMAN TRANSFERRIN RECEPTOR AND METHODS OF USE
IL261188B (en)	2016-03-04	2022-08-01	Jn Biosciences Llc	An anti-tigit antibody that binds to the tigit polypeptide on one or more amino acid residues
MA45328A (en)	2016-04-01	2019-02-06	Avidity Biosciences Llc	NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
JP7109007B2 (en)	2016-06-27	2022-07-29	ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア	Cancer treatment combination
CA3033082A1 (en)	2016-08-06	2018-02-15	Ossianix, Inc.	In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use
US20200017588A1 (en)*	2016-10-14	2020-01-16	Dana-Farber Cancer Institute, Inc.	Modular tetravalent bispecific antibody platform
US10597438B2 (en)	2016-12-14	2020-03-24	Janssen Biotech, Inc.	PD-L1 binding fibronectin type III domains
BR112019012154A2 (en)	2016-12-14	2019-11-12	Janssen Biotech Inc	cd8a-binding fibronectin type iii domains
US10611823B2 (en)	2016-12-14	2020-04-07	Hanssen Biotech, Inc	CD137 binding fibronectin type III domains
AR110586A1 (en)*	2016-12-26	2019-04-10	Japan Chem Res	HUMAN ANTITRANSFERRINE RECEPTOR ANTIBODY THAT PENETRATES THE HEMATOENCEPHALIC BARRIER
EP3561058A4 (en)	2016-12-26	2020-07-22	JCR Pharmaceuticals Co., Ltd.	FUSION PROTEIN WITH BDNF
KR20240172236A (en)	2017-01-06	2024-12-09	어비디티 바이오사이언시스 인크.	Nucleic acid-polypeptide compositions and methods of inducing exon skipping
HUE060983T2 (en)	2017-02-17	2023-05-28	Denali Therapeutics Inc	Engineered transferrin receptor binding polypeptides
US10457717B2 (en)	2017-02-17	2019-10-29	Denali Therapeutics Inc.	Engineered polypeptides
US10143187B2 (en)	2017-02-17	2018-12-04	Denali Therapeutics Inc.	Transferrin receptor transgenic models
KR102637590B1 (en)*	2017-02-17	2024-02-15	데날리 테라퓨틱스 인크.	Transferrin receptor gene insertion model
AU2018231127A1 (en)	2017-03-09	2019-09-19	Cytomx Therapeutics, Inc.	CD147 antibodies, activatable CD147 antibodies, and methods of making and use thereof
JOP20190248A1 (en)	2017-04-21	2019-10-20	Amgen Inc	Trem2 antigen binding proteins and uses thereof
US11208458B2 (en)	2017-06-07	2021-12-28	Regeneron Pharmaceuticals, Inc.	Compositions and methods for internalizing enzymes
GB201711809D0 (en)	2017-07-21	2017-09-06	Governors Of The Univ Of Alberta	Antisense oligonucleotide
EP3661555B1 (en)*	2017-08-01	2025-04-16	Ab Therapeutics, Inc.	Bispecific antibodies and uses thereof
CA3071634A1 (en)	2017-08-02	2019-02-07	Stressmarq Biosciences Inc.	Antibody binding active alpha-synuclein
CN111094336A (en)*	2017-08-10	2020-05-01	戴纳立制药公司	Affinity-Based Methods Using Transferrin Receptor Binding Proteins
KR20200058510A (en)	2017-10-02	2020-05-27	데날리 테라퓨틱스 인크.	Fusion protein containing enzyme replacement therapy enzyme
US11111297B2 (en)	2017-11-17	2021-09-07	Merck Sharp & Dohme Corp.	Antibodies specific for immunoglobulin-like transcript 3 (ILT3) and uses thereof
CN118638787A (en)	2017-12-06	2024-09-13	艾维迪提生物科学公司	Compositions and methods for treating muscular dystrophy and myotonic dystrophy
EP3737701A1 (en)*	2018-01-10	2020-11-18	Denali Therapeutics Inc.	Transferrin receptor-binding polypeptides and uses thereof
BR112020013305A2 (en)*	2018-02-05	2021-02-02	Jcr Pharmaceuticals Co., Ltd.	conjugate of an anti-human transferrin receptor antibody and an agent, pharmaceutical compositions to improve muscle function, to alleviate muscle dysfunctions associated with lysosomal disease, fabry's disease and pompe's disease, use of the conjugate, and, method for release an agent in the muscle
JP2021512899A (en)*	2018-02-07	2021-05-20	リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	Methods and Compositions for Therapeutic Protein Delivery
MA52626A (en)	2018-05-17	2021-03-24	Regeneron Pharma	ANTI-CD63 ANTIBODIES, CONJUGATES AND THEIR USES
CN112312922B (en)	2018-06-21	2025-04-11	诺和诺德股份有限公司	New compounds for treating obesity
MX2021001281A (en)	2018-08-02	2021-07-15	Dyne Therapeutics Inc	Muscle targeting complexes and uses thereof for treating dystrophinopathies.
US12097263B2 (en)	2018-08-02	2024-09-24	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating myotonic dystrophy
WO2020028831A1 (en)*	2018-08-02	2020-02-06	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating fibrodysplasia ossificans progressiva
US11911484B2 (en)	2018-08-02	2024-02-27	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11168141B2 (en)	2018-08-02	2021-11-09	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12018087B2 (en)	2018-08-02	2024-06-25	Dyne Therapeutics, Inc.	Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
MX2021001284A (en)	2018-08-02	2021-07-15	Dyne Therapeutics Inc	Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy.
CN112839955A (en)*	2018-08-16	2021-05-25	戴纳立制药公司	Engineered bispecific proteins
CN109336973B (en)*	2018-10-11	2021-08-24	中国科学院昆明动物研究所	Anti-transferrin antibody and its use
KR102692543B1 (en)	2018-10-26	2024-08-07	재단법인 목암생명과학연구소	Fusion protein comprising ids and use thereof
IL312067B1 (en)*	2018-12-21	2025-04-01	Avidity Biosciences Inc	Anti-transferrin receptor antibodies and uses thereof
MX2021007797A (en)*	2018-12-28	2021-10-26	Kyowa Kirin Co Ltd	BISPECIFIC ANTIBODY BINDING TO TfR.
CN114650844A (en)	2019-09-23	2022-06-21	西托姆克斯治疗公司	anti-CD 47 antibodies, activatable anti-CD 47 antibodies, and methods of use thereof
EP4045061A4 (en)*	2019-10-14	2024-04-17	ARO Biotherapeutics Company	CD71-BINDING FIBRONECTIN TYPE III DOMAINS
WO2021076574A2 (en)	2019-10-14	2021-04-22	Aro Biotherapeutics Company	Fn3 domain-sirna conjugates and uses thereof
WO2021092482A1 (en)*	2019-11-06	2021-05-14	The Regents Of The University Of California	Compositions and methods for transferrin receptor 1 targeting
MX2022007486A (en)	2019-12-23	2022-06-29	Denali Therapeutics Inc	PROGRANULIN VARIANTS.
CN114930170A (en)	2020-01-02	2022-08-19	豪夫迈·罗氏有限公司	Method for determining the amount of therapeutic antibody in the brain
WO2021142260A1 (en)*	2020-01-10	2021-07-15	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for modulation of acvr1
WO2021168734A1 (en)*	2020-02-27	2021-09-02	世延生医股份有限公司	Monoclonal antibody of matrix metalloproteinase 1, detection kit and detection method thereof
EP4121063A4 (en)	2020-03-19	2024-07-03	Avidity Biosciences, Inc.	Compositions and methods of treating facioscapulohumeral muscular dystrophy
AU2021241682A1 (en)	2020-03-27	2022-10-13	Avidity Biosciences, Inc.	Compositions and methods of treating muscle dystrophy
CA3179911A1 (en)*	2020-04-08	2021-10-14	Janssen Biotech, Inc.	Compositions and methods for blood-brain barrier delivery
AU2021284273A1 (en)	2020-06-02	2022-12-15	Arcus Biosciences, Inc.	Antibodies to TIGIT
BR112023021325A2 (en)	2021-04-14	2023-12-19	Aro Biotherapeutics Company	CD71-BINDING TYPE III FIBRONECTIN DOMAINS
US12239710B2 (en)	2021-04-14	2025-03-04	Aro Biotherapeutics Company	FN3 domain-siRNA conjugates and uses thereof
AR125406A1 (en)*	2021-04-23	2023-07-12	Univ Pennsylvania	NEW COMPOSITIONS WITH SELECTIVE MOTIVES FOR THE BRAIN AND COMPOSITIONS CONTAINING THEM
US11633498B2 (en)	2021-07-09	2023-04-25	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11648318B2 (en)	2021-07-09	2023-05-16	Dyne Therapeutics, Inc.	Anti-transferrin receptor (TFR) antibody and uses thereof
US11969475B2 (en)	2021-07-09	2024-04-30	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
IL309936A (en)	2021-07-09	2024-03-01	Dyne Therapeutics Inc	Muscle targeting complexes and formulations for treating dystrophinopathies
US11638761B2 (en)	2021-07-09	2023-05-02	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11771776B2 (en)	2021-07-09	2023-10-03	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating dystrophinopathies
US20240317877A1 (en)*	2021-07-15	2024-09-26	(Iucf-Hyu (Industry-University Cooperation Foundation Hanyang University))	Anti-human transferrin receptor antibody having improved blood-brain-barrier permeability, and multi-specific antibody and pharmaceutical composition which use same
WO2023034409A1 (en)	2021-09-01	2023-03-09	Biogen Ma Inc.	Anti-transferrin receptor antibodies and uses thereof
CN118265544A (en)	2021-09-16	2024-06-28	艾维迪提生物科学公司	Compositions and methods for treating facioscapulohumeral muscular dystrophy
KR20250004770A (en)	2022-04-15	2025-01-08	다인 세라퓨틱스, 인크.	Muscle-targeting complexes and preparations for treating myotonic dystrophy
AU2023316021A1 (en)	2022-07-29	2025-03-06	Alector Llc	Cd98hc antigen-binding domains and uses therefor
IL317261A (en)	2022-07-29	2025-01-01	Regeneron Pharma	Non-human animals comprising a modified transferrin receptor locus
AU2023314923A1 (en)	2022-07-29	2025-02-27	Regeneron Pharmaceuticals, Inc.	Viral particles retargeted to transferrin receptor 1
KR20250044671A (en)	2022-07-29	2025-04-01	알렉터 엘엘씨	Transferrin receptor antigen-binding domain and uses thereof
WO2024036333A2 (en)	2022-08-12	2024-02-15	Epibiologics, Inc.	Degradation of egfr using a bispecific binding agent
WO2024155066A1 (en)*	2023-01-16	2024-07-25	주식회사 시그널바이오	Anti-human transferrin receptor antibody with improved blood-brain-barrier permeability, and multispecific antibody and pharmaceutical composition using same
WO2024206161A1 (en)*	2023-03-24	2024-10-03	Denali Therapeutics Inc.	Abeta-targeting proteins and methods of use
WO2024200271A1 (en)	2023-03-24	2024-10-03	Bioarctic Ab	Antibody binding to the protease-like domain of the human transferrin receptor htfr1
WO2025024334A1 (en)	2023-07-21	2025-01-30	Marrow Therapeutics, Inc.	Hematopoietic cell targeting conjugates and related methods
WO2025021790A2 (en)	2023-07-24	2025-01-30	F. Hoffmann-La Roche Ag	Multispecific antibodies

Family Cites Families (142)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20559A (en)		1858-06-15		Reducing wheel-tires
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4737456A (en)	1985-05-09	1988-04-12	Syntex (U.S.A.) Inc.	Reducing interference in ligand-receptor binding assays
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US6548640B1 (en)	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
JPS633262A (en)*	1986-06-24	1988-01-08	Toshiba Corp	Method and instrument for analyzing reticulocyte
US5567610A (en)	1986-09-04	1996-10-22	Bioinvent International Ab	Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en)	1987-03-18	1990-08-16	Sb2, Inc.	Altered antibodies
US5606040A (en)	1987-10-30	1997-02-25	American Cyanamid Company	Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en)	1987-10-30	1998-06-23	American Cyanamid Company	Process for preparing targeted forms of methyltrithio antitumor agents
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
EP0368684B2 (en)	1988-11-11	2004-09-29	Medical Research Council	Cloning immunoglobulin variable domain sequences.
US5175384A (en)	1988-12-05	1992-12-29	Genpharm International	Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (en)	1989-06-22	1991-01-17	Behringwerke Ag	BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5672683A (en)*	1989-09-07	1997-09-30	Alkermes, Inc.	Transferrin neuropharmaceutical agent fusion protein
AU675057B2 (en)*	1989-09-07	1997-01-23	Alkermes, Inc.	Process for the preparation of transferrin receptor specificantibody-neuropharmaceutical or diagnostic agent conjugates
CA2026147C (en)	1989-10-25	2006-02-07	Ravi J. Chari	Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en)	1989-10-25	1993-05-04	Immunogen Inc.	Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en)	1989-10-27	1999-09-28	The Scripps Research Institute	Transgenic plants expressing assembled secretory antibodies
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5229275A (en)	1990-04-26	1993-07-20	Akzo N.V.	In-vitro method for producing antigen-specific human monoclonal antibodies
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
CA2095633C (en)	1990-12-03	2003-02-04	Lisa J. Garrard	Enrichment method for variant proteins with altered binding properties
US5571894A (en)	1991-02-05	1996-11-05	Ciba-Geigy Corporation	Recombinant antibodies specific for a growth factor receptor
WO1992022653A1 (en)	1991-06-14	1992-12-23	Genentech, Inc.	Method for making humanized antibodies
GB9114948D0 (en)	1991-07-11	1991-08-28	Pfizer Ltd	Process for preparing sertraline intermediates
IE922437A1 (en)	1991-07-25	1993-01-27	Idec Pharma Corp	Recombinant antibodies for human therapy
US7018809B1 (en)	1991-09-19	2006-03-28	Genentech, Inc.	Expression of functional antibody fragments
US5565332A (en)	1991-09-23	1996-10-15	Medical Research Council	Production of chimeric antibodies - a combinatorial approach
US5587458A (en)	1991-10-07	1996-12-24	Aronex Pharmaceuticals, Inc.	Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en)	1991-11-04	1993-05-13	The Regents Of The University Of California	Compositions that mediate killing of hiv-infected cells
CA2372813A1 (en)	1992-02-06	1993-08-19	L.L. Houston	Biosynthetic binding protein for cancer marker
ATE244763T1 (en)	1992-02-11	2003-07-15	Cell Genesys Inc	ACHIEVEMENT OF HOMOZYGOTE THROUGH TARGETED GENETIC EVENTS
US5573905A (en)	1992-03-30	1996-11-12	The Scripps Research Institute	Encoded combinatorial chemical libraries
AU677216B2 (en)	1992-07-27	1997-04-17	Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The	Targeting of liposomes to the blood-brain barrier
ATE196606T1 (en)	1992-11-13	2000-10-15	Idec Pharma Corp	THERAPEUTIC USE OF CHIMERIC AND LABELED ANTIBODIES DIRECTED AGAINST A DIFFERENTIATION ANTIGEN WHICH EXPRESSION IS RESTRICTED TO HUMAN B LYMPHOCYTES, FOR THE TREATMENT OF B-CELL LYMPHOMA
US5635483A (en)	1992-12-03	1997-06-03	Arizona Board Of Regents Acting On Behalf Of Arizona State University	Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en)	1993-01-26	1998-07-14	Arizona Board Of Regents	Elucidation and synthesis of selected pentapeptides
CA2163345A1 (en)	1993-06-16	1994-12-22	Susan Adrienne Morgan	Antibodies
US5773001A (en)	1994-06-03	1998-06-30	American Cyanamid Company	Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5789199A (en)	1994-11-03	1998-08-04	Genentech, Inc.	Process for bacterial production of polypeptides
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US5840523A (en)	1995-03-01	1998-11-24	Genetech, Inc.	Methods and compositions for secretion of heterologous polypeptides
US5869046A (en)	1995-04-14	1999-02-09	Genentech, Inc.	Altered polypeptides with increased half-life
US6015555A (en)*	1995-05-19	2000-01-18	Alkermes, Inc.	Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5714586A (en)	1995-06-07	1998-02-03	American Cyanamid Company	Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en)	1995-06-07	1998-01-27	American Cyanamid Company	Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en)	1995-07-27	2001-07-31	Genentech, Inc.	Protein formulation
GB9603256D0 (en)	1996-02-16	1996-04-17	Wellcome Found	Antibodies
US6171586B1 (en)	1997-06-13	2001-01-09	Genentech, Inc.	Antibody formulation
PT994903E (en)	1997-06-24	2005-10-31	Genentech Inc	METHODS AND COMPOSITIONS FOR GALACTOSILED GLICOPROTEINS
US6040498A (en)	1998-08-11	2000-03-21	North Caroline State University	Genetically engineered duckweed
WO1999022764A1 (en)	1997-10-31	1999-05-14	Genentech, Inc.	Methods and compositions comprising glycoprotein glycoforms
US6610833B1 (en)	1997-11-24	2003-08-26	The Institute For Human Genetics And Biochemistry	Monoclonal human natural antibodies
ES2375931T3 (en)	1997-12-05	2012-03-07	The Scripps Research Institute	HUMANIZATION OF ANTIBODY MURINO.
WO1999051642A1 (en)	1998-04-02	1999-10-14	Genentech, Inc.	Antibody variants and fragments thereof
US6194551B1 (en)	1998-04-02	2001-02-27	Genentech, Inc.	Polypeptide variants
AU3657899A (en)	1998-04-20	1999-11-08	James E. Bailey	Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
HUP0104865A3 (en)	1999-01-15	2004-07-28	Genentech Inc	Polypeptide variants with altered effector function
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
EP3031917A1 (en)	1999-04-09	2016-06-15	Kyowa Hakko Kirin Co., Ltd.	Method for controlling the activity of immunologically functional molecule
ATE303445T1 (en)	1999-10-04	2005-09-15	Medicago Inc	METHOD FOR REGULATION OF TRANSCRIPTION OF FOREIGN GENES IN THE PRESENCE OF NITROGEN
US7125978B1 (en)	1999-10-04	2006-10-24	Medicago Inc.	Promoter for regulating expression of foreign genes
JP4668498B2 (en)	1999-10-19	2011-04-13	協和発酵キリン株式会社	Method for producing polypeptide
IL149809A0 (en)	1999-12-15	2002-11-10	Genentech Inc	Shotgun scanning, a combinatorial method for mapping functional protein epitopes
JP2003531821A (en)	1999-12-29	2003-10-28	イムノージェンインコーポレーテッド	Cytotoxic drugs containing modified doxorubicin and daunorubicin and their therapeutic use
UA75881C2 (en)	2000-02-24	2006-06-15	Univ Washington	A humanized antibody being associated with beta-amyloid peptide ((a?- polynucleic acid coding it, a pharmaceutical composition containing it, and use of said humanized antibody for making medicinal agent for prophylaxis and treatment of states associated with formation of beta-amyloid plaques
HUP0300369A2 (en)	2000-04-11	2003-06-28	Genentech, Inc.	Multivalent antibodies and uses therefor
JP5362164B2 (en)	2000-07-07	2013-12-11	バイオアークティックニューロサイエンスアーベー	Prevention and treatment of Alzheimer's disease
WO2002031140A1 (en)	2000-10-06	2002-04-18	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions
US6946292B2 (en)	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en)	2000-10-06	2006-06-20	Kyowa Hakko Kogyo Co., Ltd.	Process for purifying antibody
US6596541B2 (en)	2000-10-31	2003-07-22	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
CA2430013C (en)	2000-11-30	2011-11-22	Medarex, Inc.	Transgenic transchromosomal rodents for making human antibodies
TWI255272B (en)	2000-12-06	2006-05-21	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
AU2002248184C1 (en)	2000-12-12	2018-01-04	Board Of Regents, The University Of Texas System	Molecules with extended half-lives, compositions and uses thereof
NZ581474A (en)	2001-08-03	2011-04-29	Glycart Biotechnology Ag	Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
WO2003016466A2 (en)	2001-08-17	2003-02-27	Eli Lilly And Company	ANTI-Aβ ANTIBODIES
US20040241164A1 (en)	2001-08-17	2004-12-02	Bales Kelly Renee	Use of antibodies having high affinity for soluble ab to treat conditions and diseases related to ass
ATE430580T1 (en)	2001-10-25	2009-05-15	Genentech Inc	GLYCOPROTEIN COMPOSITIONS
US20040093621A1 (en)	2001-12-25	2004-05-13	Kyowa Hakko Kogyo Co., Ltd	Antibody composition which specifically binds to CD20
MY139983A (en)	2002-03-12	2009-11-30	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
WO2003085118A1 (en)	2002-04-09	2003-10-16	Kyowa Hakko Kogyo Co., Ltd.	Process for producing antibody composition
ES2362419T3 (en)	2002-04-09	2011-07-05	Kyowa Hakko Kirin Co., Ltd.	CELLS WITH DEPRESSION OR DELETION OF THE ACTIVITY OF THE PROTEIN THAT PARTICIPATES IN THE TRANSPORT OF GDP-FUCOSA.
CA2481920A1 (en)	2002-04-09	2003-10-16	Kyowa Hakko Kogyo Co., Ltd.	Antibody composition-containing medicament
EP1502603A4 (en)	2002-04-09	2006-12-13	Kyowa Hakko Kogyo Kk	DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM Fc gamma RIIIa POLYMORPHISM
US20040259150A1 (en)	2002-04-09	2004-12-23	Kyowa Hakko Kogyo Co., Ltd.	Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
MXPA04009924A (en)	2002-04-09	2005-07-01	Kyowa Hakko Kogyo Kk	Cells with modified genome.
CA2488441C (en)	2002-06-03	2015-01-27	Genentech, Inc.	Synthetic antibody phage libraries
DE60333306D1 (en)*	2002-08-30	2010-08-19	Biorexis Pharmaceutical Corp	MODIFIED TRANSFERRIN FUSION PROTEINS WITH DOUBLE TRANSFERRIN AMINO OR CARBOXY TERMINALS DOMAINS
WO2004029629A1 (en)	2002-09-27	2004-04-08	Janssen Pharmaceutica N.V.	N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
BR0315157A (en)	2002-10-09	2005-08-09	Rinat Neuroscience Corp	Methods of treating alzheimer's disease by employing antibodies directed against amyloid beta peptide and compositions thereof
US7361740B2 (en)	2002-10-15	2008-04-22	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US20050142141A1 (en)	2002-11-27	2005-06-30	Pardridge William M.	Delivery of enzymes to the brain
PL212899B1 (en)	2002-12-16	2012-12-31	Genentech Inc	Immunoglobulin variants and uses thereof
CA2510003A1 (en)	2003-01-16	2004-08-05	Genentech, Inc.	Synthetic antibody phage libraries
US7871607B2 (en)	2003-03-05	2011-01-18	Halozyme, Inc.	Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en)	2003-03-05	2006-05-18	Halozyme, Inc.	Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
WO2005028511A2 (en)	2003-03-28	2005-03-31	Centocor, Inc.	Anti-amyloid antibodies, compositions, methods and uses
PE20050627A1 (en)	2003-05-30	2005-08-10	Wyeth Corp	HUMANIZED ANTIBODIES THAT RECOGNIZE THE BETA AMYLOID PEPTIDE
JP4794301B2 (en)*	2003-06-11	2011-10-19	中外製薬株式会社	Antibody production method
WO2005035586A1 (en)	2003-10-08	2005-04-21	Kyowa Hakko Kogyo Co., Ltd.	Fused protein composition
AU2004280065A1 (en)	2003-10-09	2005-04-21	Kyowa Hakko Kirin Co., Ltd.	Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase
MX337587B (en)	2003-11-05	2016-03-11	Glycart Biotechnology Ag	Antigen binding molecules with increased fc receptor binding affinity and effector function.
SG10201701737XA (en)	2003-11-06	2017-04-27	Seattle Genetics Inc	Monomethylvaline compounds capable of conjugation to ligands
WO2005053742A1 (en)	2003-12-04	2005-06-16	Kyowa Hakko Kogyo Co., Ltd.	Medicine containing antibody composition
US7527791B2 (en)	2004-03-31	2009-05-05	Genentech, Inc.	Humanized anti-TGF-beta antibodies
US7785903B2 (en)	2004-04-09	2010-08-31	Genentech, Inc.	Variable domain library and uses
EP2357201B1 (en)	2004-04-13	2017-08-30	F. Hoffmann-La Roche AG	Anti-P-selectin antibodies
ES2379526T3 (en)	2004-04-30	2012-04-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anti-TfR antibody
AU2005252699B2 (en)*	2004-06-07	2010-12-23	Macrogenics West, Inc.	Transferrin receptor antibodies
AU2005290250A1 (en)	2004-07-30	2006-04-06	Rinat Neuroscience Corp.	Antibodies directed against amyloid-beta peptide and methods using same
TWI309240B (en)	2004-09-17	2009-05-01	Hoffmann La Roche	Anti-ox40l antibodies
ES2669510T3 (en)	2004-09-23	2018-05-28	Genentech, Inc.	Antibodies and conjugates engineered with cysteine
WO2006039470A2 (en)	2004-09-29	2006-04-13	Centocor, Inc.	Anti- amyloid antibodies, compositions, methods and uses
JO3000B1 (en)	2004-10-20	2016-09-05	Genentech Inc	Antibody Formulations.
US8802820B2 (en)*	2004-11-12	2014-08-12	Xencor, Inc.	Fc variants with altered binding to FcRn
AR051800A1 (en)	2004-12-15	2007-02-07	Wyeth Corp	BETA ANTIBODIES USED TO IMPROVE COGNITION
TW200636066A (en)	2004-12-15	2006-10-16	Elan Pharm Inc	Humanized antibodies that recognize beta amyloid peptide
WO2006066089A1 (en)	2004-12-15	2006-06-22	Neuralab Limited	Humanized amyloid beta antibodies for use in improving cognition
ES2259270B1 (en)	2005-03-09	2007-11-01	Consejo Superior De Investigaciones Cientificas	IN VITRO DIAGNOSTIC METHOD OF ALZHEIMER'S DISEASE BY A MONOCLONAL ANTIBODY.
US8053569B2 (en)*	2005-10-07	2011-11-08	Armagen Technologies, Inc.	Nucleic acids encoding and methods of producing fusion proteins
EP1957531B1 (en)	2005-11-07	2016-04-13	Genentech, Inc.	Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
WO2007064919A2 (en)	2005-12-02	2007-06-07	Genentech, Inc.	Binding polypeptides with restricted diversity sequences
JP5419131B2 (en)	2005-12-12	2014-02-19	エーシーイミューンソシエテアノニム	Β1-42 specific monoclonal antibodies with therapeutic properties
AR060871A1 (en)	2006-05-09	2008-07-16	Genentech Inc	UNION OF POLYPEPTIDES WITH OPTIMIZED SUPERCONTIGES
NZ574188A (en)	2006-07-14	2012-05-25	Ac Immune Sa	Humanized antibody against amyloid beta
DK2059533T3 (en)	2006-08-30	2013-02-25	Genentech Inc	MULTI-SPECIFIC ANTIBODIES
US20080226635A1 (en)	2006-12-22	2008-09-18	Hans Koll	Antibodies against insulin-like growth factor I receptor and uses thereof
CN101245107B (en)*	2007-02-14	2010-10-13	中国人民解放军军事医学科学院生物工程研究所	Antihuman transferrin acceptor human source antibody and uses thereof
CN100592373C (en)	2007-05-25	2010-02-24	群康科技(深圳)有限公司	Liquid crystal panel drive device and its drive method
ES2529174T3 (en)	2007-06-12	2015-02-17	Ac Immune S.A.	Humanized antibodies for beta amyloid
KR20160017126A (en)	2007-06-12	2016-02-15	에이씨 이뮨 에스.에이.	Monoclonal anti beta amyloid antibody
WO2009027105A2 (en)	2007-08-31	2009-03-05	Neurimmune Therapeutics Ag	Method of providing patient specific immune response in amyloidoses and protein aggregation disorders
DK2235064T3 (en)	2008-01-07	2016-01-11	Amgen Inc	A process for the preparation of heterodimeric Fc molecules using electrostatic control effects
UA117801C2 (en)*	2010-11-30	2018-10-10	Дженентек, Інк.	Low affinity blood brain barrier receptor antibodies and uses therefor
AU2012234335B2 (en)	2011-03-29	2016-09-01	Roche Glycart Ag	Antibody Fc variants
TW201400132A (en)	2012-05-21	2014-01-01	Genentech Inc	Methods for improving safety of blood-brain barrier transport
EP3221362B1 (en)*	2014-11-19	2019-07-24	F.Hoffmann-La Roche Ag	Anti-transferrin receptor antibodies and methods of use

2014
- 2014-05-20KRKR1020157035600Apatent/KR102293064B1/enactiveActive
- 2014-05-20AUAU2014268726Apatent/AU2014268726B2/enactiveActive
- 2014-05-20PEPE2015002420Apatent/PE20151926A1/enunknown
- 2014-05-20HRHRP20240107TTpatent/HRP20240107T1/enunknown
- 2014-05-20PLPL19190228.7Tpatent/PL3594240T3/enunknown
- 2014-05-20SGSG11201509566RApatent/SG11201509566RA/enunknown
- 2014-05-20ESES19190228Tpatent/ES2970063T3/enactiveActive
- 2014-05-20MXMX2015015970Apatent/MX380520B/enunknown
- 2014-05-20CNCN201480035703.6Apatent/CN105358578B/enactiveActive
- 2014-05-20MAMA38632Apatent/MA38632B1/enunknown
- 2014-05-20ARARP140102008Apatent/AR096364A1/enunknown
- 2014-05-20PHPH1/2021/550015Apatent/PH12021550015A1/enunknown
- 2014-05-20CACA2908743Apatent/CA2908743C/enactiveActive
- 2014-05-20PEPE2020002132Apatent/PE20210649A1/enunknown
- 2014-05-20UAUAA201512536Apatent/UA119235C2/enunknown
- 2014-05-20WOPCT/US2014/038847patent/WO2014189973A2/enactiveApplication Filing
- 2014-05-20USUS14/283,038patent/US9708406B2/enactiveActive
- 2014-05-20EPEP19190228.7Apatent/EP3594240B1/enactiveActive
- 2014-05-20JPJP2016515030Apatent/JP6612214B2/enactiveActive
- 2014-05-20EPEP23210472.9Apatent/EP4324480A3/enactivePending
- 2014-05-20HUHUE19190228Apatent/HUE065593T2/enunknown
- 2014-05-20EPEP14732721.7Apatent/EP2999716A2/ennot_activeCeased
- 2014-05-20TWTW103117676Apatent/TWI573805B/enactive
- 2014-05-20EAEA201592213Apatent/EA038367B1/enunknown
- 2014-05-20ILIL242088Apatent/IL242088B2/enunknown
- 2014-05-20SGSG10202003997UApatent/SG10202003997UA/enunknown
2015
- 2015-11-12PHPH12015502565Apatent/PH12015502565B1/enunknown
- 2015-11-19CRCR20150618Apatent/CR20150618A/enunknown
- 2015-11-20CLCL2015003406Apatent/CL2015003406A1/enunknown
2016
- 2016-03-24HKHK16103512.5Apatent/HK1215584A1/enunknown
2017
- 2017-06-05USUS15/614,149patent/US10808036B2/enactiveActive
2020
- 2020-01-17AUAU2020200355Apatent/AU2020200355A1/ennot_activeAbandoned
- 2020-09-01USUS17/008,941patent/US20210087288A1/ennot_activeAbandoned
2022
- 2022-03-15AUAU2022201773Apatent/AU2022201773A1/ennot_activeAbandoned
2023
- 2023-07-04ILIL304243Apatent/IL304243A/enunknown

Publication number	Publication date
KR20160011198A (en)	2016-01-29
AU2022201773A1 (en)	2022-04-07
US20180002433A1 (en)	2018-01-04
IL242088A (en)	2015-12-31
CA2908743A1 (en)	2014-11-27
PH12015502565A1 (en)	2016-02-29
AU2014268726A1 (en)	2015-11-19
KR102293064B1 (en)	2021-08-23
EP2999716A2 (en)	2016-03-30
EP4324480A3 (en)	2024-05-08
HK1215584A1 (en)	2016-09-02
UA119235C2 (en)	2019-05-27
BR112015029009A2 (en)	2017-09-19
PE20210649A1 (en)	2021-03-26
EP3594240C0 (en)	2023-12-06
PE20151926A1 (en)	2016-01-07
CN105358578B (en)	2021-08-06
EA201592213A1 (en)	2016-04-29
EP3594240B1 (en)	2023-12-06
IL242088B2 (en)	2023-12-01
ES2970063T3 (en)	2024-05-24
SG10202003997UA (en)	2020-06-29
CL2015003406A1 (en)	2016-07-15
TWI573805B (en)	2017-03-11
US20210087288A1 (en)	2021-03-25
PL3594240T3 (en)	2024-04-02
US9708406B2 (en)	2017-07-18
PH12021550015A1 (en)	2022-05-11
HRP20240107T1 (en)	2024-04-12
AR096364A1 (en)	2015-12-23
AU2014268726B2 (en)	2019-10-31
AU2020200355A1 (en)	2020-02-06
US10808036B2 (en)	2020-10-20
EP3594240A1 (en)	2020-01-15
HUE065593T2 (en)	2024-06-28
JP6612214B2 (en)	2019-11-27
MA38632B1 (en)	2019-10-31
IL242088B1 (en)	2023-08-01
PH12015502565B1 (en)	2016-02-29
TW201500373A (en)	2015-01-01
US20150110791A1 (en)	2015-04-23
CR20150618A (en)	2016-02-08
EA038367B1 (en)	2021-08-16
WO2014189973A2 (en)	2014-11-27
JP2016526878A (en)	2016-09-08
CN105358578A (en)	2016-02-24
IL304243A (en)	2023-09-01
MA38632A1 (en)	2018-09-28
CA2908743C (en)	2024-06-25
EP4324480A2 (en)	2024-02-21
MX380520B (en)	2025-03-12
MX2015015970A (en)	2016-09-08
WO2014189973A3 (en)	2015-03-05

Publication	Publication Date	Title
IL304243A (en)	2023-09-01	Anti-transferrin receptor antibodies and methods of use
IL272279A (en)	2020-02-27	Chimeric antigen receptor and methods of use thereof
IL280155A (en)	2021-03-01	Anti-siglec-8 antibodies and methods of use thereof
IL290547A (en)	2022-04-01	Antibodies and methods of use
ZA201603308B (en)	2019-11-27	Novel anti-claudin antibodies and methods of use
IL244495A0 (en)	2016-04-21	Anti-alpha-synuclein antibodies and methods of use
IL245946A0 (en)	2016-07-31	Novel anti-dpep3 antibodies and methods of use
HK1225612A1 (en)	2017-09-15	Anti-ly6e antibodies and methods of use

Movatterモバイル変換

SG11201509566RA - Anti-transferrin receptor antibodies and methods of use - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (1)

Family

ID=50983167

Family Applications (2)

Family Applications After (1)

Country Status (25)

Families Citing this family (89)

Family Cites Families (142)

Also Published As

Similar Documents